Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Diagnostic Test Uses Light to Detect Malaria without Blood Samples

By LabMedica International staff writers
Posted on 09 Jan 2023
Print article
Image: Non-invasive malaria screening device uses light for diagnosis (Photo courtesy of Pexels)
Image: Non-invasive malaria screening device uses light for diagnosis (Photo courtesy of Pexels)

Rapid tests, which are easy to deploy and require minimal equipment, provide an important diagnostic tool in the ongoing effort against malaria, which affects more than 250 million people around the world annually. While the advent of these tests has greatly advanced diagnosis in regions where the disease is endemic, they still involve invasive blood draws from patients, which require skilled medical personnel and pose additional safety risks. Now, a team of scientists is developing an alternative: a rapid diagnostic test that uses light to diagnose the often deadly disease - no blood draws or finger pricks needed.

Current rapid malaria tests involve applying a blood sample to a testing strip that can detect the presence of malaria-causing plasmodium parasites in red blood cells. Such tests can be administered at the point of care and provide results in about 20 minutes, but also are inadequate for detection of asymptomatic infections where the level of parasites in blood is low. The team of scientists led by Johns Hopkins University (Baltimore, MD, USA) has improved on that model through the development of a hand-held screening device that can scan a patient’s arm or finger to detect the presence of malaria, eliminating the need to draw blood. Called ParaSpy Plus, the technology depends on an optical fiber probe that combines two spectroscopy modalities, label-free Raman spectroscopy and diffuse reflectance spectroscopy, or DRS, to noninvasively quantify malaria parasites in red blood cells.

Thanks to the fiber probe, Raman and DRS measurements are sequentially performed in vivo without sampling blood. When collected by the device, the measurements will then directly feed into artificial intelligence algorithms that can provide a quick and accurate diagnosis. The team plans to integrate its new sensing technology and AI software into a single portable screening device. And without any blood draws or sample preparation, the device can be used to screen for malaria outside of a clinical setting, such as in schools or community centers. The team expects that at the end of the three-year project period, the prototype will be ready for large-scale validation via clinical studies in different malaria-endemic regions. ParaSpy Plus will also be adaptable to the diagnosis and treatment of many other diseases, according to the team.

“With our proposed method, there are no invasive finger-pricks. Instead, we are working on a way to diagnose whether a person has malaria through non-invasive measurements using near-infrared light,” said team leader Ishan Barman, an associate professor of mechanical engineering in the Whiting School of Engineering. “The secondary goal of our work is to explore the capability of this platform for the diagnosis of diseases with high prevalence among the same populations, such as anemia and sickle cell disease.”

Related Links:
Johns Hopkins University 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.